Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 14 of 151

  1. ARO-INHBE

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  2. ARO-MAPT-SC

    Arrowhead Pharmaceuticals Ireland Limited

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  3. ARO-MMP7 Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  4. ARO-MUC5AC

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 2 small molecule terminated

    1 trial

  5. ARO-RAGE

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 2 small molecule active

    2 trials

  6. ARODM1-1001

    Sarepta Therapeutics

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  7. AROMUC5AC-1001

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma and Chronic obstructive pulmonary disease

    phase 2 small molecule active

    1 trial

  8. ARQ-151 cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 2 small molecule completed

    1 trial

  9. ARQ-151 cream 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    2 trials

  10. ARQ-151 cream 0.5%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    1 trial

  11. ARQ-154

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  12. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Chronic Hand Eczema

    phase 2 small molecule completed

    1 trial

  13. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Vitiligo

    phase 2 small molecule terminated

    1 trial

  14. ARS-1

    Ars Pharmaceuticals Irl Limited

    Urticaria

    phase 2 small molecule completed

    1 trial

  15. ARS-1

    Ars Pharmaceuticals Irl Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  16. ART0380C001

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Solid Tumours

    phase 2 small molecule active

    1 trial

  17. ART27.13-100

    ARTELO BIOSCIENCES, INC.

    Cancer Anorexia

    phase 2 small molecule active

    1 trial

  18. ART6043C001

    Lacuna Pharma Pty Ltd

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  19. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  20. AS01 adjuvant (0.5 mL intramuscular)

    Hospital Authority, Hong Kong

    Immune System Responses and Trained Immunity After AS01 Administration

    phase 2 mab active

    1 trial

  21. ASC22

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  22. ASC30 tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule active

    1 trial

  23. ASCAPE-based follow-up strategy

    ATOSSA THERAPEUTICS, INC.

    Breast Cancer

    phase 2 other active

    1 trial

  24. ASCT+CD7-CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CD7 Positive

    phase 2 small molecule active

    1 trial

  25. ASLAN001

    Hospital Authority, Hong Kong

    Advanced/ Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  26. ASLAN004-004

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  27. ASND0029

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  28. ASND0030

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  29. ASND0038

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial

  30. ASND0042

    Lacuna Pharma Pty Ltd

    Children with Achondroplasia

    phase 2 small molecule active

    1 trial

  31. ASND0045

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  32. ASP2957

    Astellas Pharma GmbH

    X-linked myotubular myopathy

    phase 2 small molecule active

    1 trial

  33. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    The George Institute

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  34. ASP5094

    Astellas Pharma Inc

    Rheumatoid Arthritis (RA)

    phase 2 small molecule completed

    1 trial

  35. ASP8273

    Astellas Pharma Inc

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  36. ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 2 small molecule active

    1 trial

  37. ASPIRE

    The George Institute

    Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.

    phase 2 small molecule active

    1 trial

  38. AST-OPC1

    Lineage Cell Therapeutics

    Cervical Spinal Cord Injury

    phase 2 mab completed

    1 trial

  39. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  40. ASTX727-07

    Taiho Pharma Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  41. AT-1501

    Eledon Pharmaceuticals

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  42. AT-1501

    Eledon Pharmaceuticals

    IgA Nephropathy

    phase 2 small molecule terminated

    1 trial

  43. AT-1501

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  44. AT-1501

    Eledon Pharmaceuticals

    Prevention of Rejection in Kidney Transplant

    phase 2 small molecule active

    1 trial

  45. AT-1501

    Eledon Pharmaceuticals

    Kidney Transplant Rejection

    phase 2 small molecule active

    2 trials

  46. AT-1501 IV Infusion

    Eledon Pharmaceuticals

    Brittle Type 1 Diabetes Mellitus

    phase 2 mab terminated

    1 trial

  47. AT-1501-K209

    Eledon Pharmaceuticals

    Prophylaxis of Renal Allograft Rejection

    phase 2 small molecule active

    1 trial

  48. AT-527

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.